In the intent-to-treat population, the change in the dyspareunia
severity score improved in the OSP group vs.
At 12 weeks, the patients with moderate or severe baseline dyspareunia
who were treated with lasofoxifene reported having a significantly greater decrease in their symptom score, compared with those who received placebo, said Dr.
(1) Nearly 40% of the respondents (3046) reported symptoms consistent with VVA--including vaginal dryness (55% of all participants), dyspareunia
(44%), irritation (37%).
(1) The involution at the level of the vestibule and hymenal carunculae leads to introital stenosis, which is often associated with dyspareunia
. The contraction of the distal vagina at the area of the hymen and transverse perineal membrane can lead to subsequent "reflex" vaginismus, but the pain associated with introital stenosis is at the perineum and hymenal "ring" rather than higher in the vagina at the area of the insertion of the levator muscles.
Furthermore, although studies describe dyspareunia
and overall sexual function in validated questionnaire scores, most do not evaluate other specific domains of sexual function.
Pelvic floor dysfunction can incorporate vaginismus, dyspareunia
, and chronic pelvic pain.
Archer and his colleagues sought to investigate whether age, time since menopause, or any previous use of hormone replacement therapy influenced prasterone's efficacy in treating dyspareunia
As is seen in the table, the prevalence of sexual dysfunction was found to be statistically significant in women who were high school graduates, who reported their economic status as middle class, who had a history of high risk pregnancy, whose menstruation did not return, who had dyspareunia
, who did not use a family planning method, who used withdrawal as a family planning method and who were at-risk for postnatal depression (p<0.05).
According to the company, Osphena is the only US FDA-approved oral pill for the treatment of moderate to severe dyspareunia
(painful sex), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.
may be common but it's a poorly understood problem with several physical and psychological causes.
Treatment of dyspareunia
and vaginal outlet distortions by perineoplasty.
Following approval by the US FDA of Intrarosa[TM] on November 17th 2016, for the treatment of dyspareunia
, a symptom of vulvovaginal atrophy due to menopause, Endoceutics focuses on developing non estrogen-based therapies for sexual dysfunction and the other symptoms of menopause, , including hot flushes, osteoporosis and muscle loss.